ClinicalTrials.gg
RecruitingNCT07362966Updated Oct 1, 2026

Precision Colchicine Intervention to Suppress Atherosclerosis in TET2 Clonal Hematopoiesis

A Phase 4 interventional study of Colchicine 0.5 mg orally once daily for 12 months. and SoC therapy in Colchicine, Coronary Atherosclerosis Management and Clonal Hematopoiesis of Indeterminate Potential, sponsored by Shenyang Northern Hospital. Recruiting at 1 site in China. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Shenyang Northern Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies testing colchicine in Coronary Artery Disease — 8 open to participants now, 10 under way, 4 of them phase 3. Colchicine · Coronary Artery Disease.

Planned enrollment
16th of 26
120 · median 175
Started
2026
with 3 others
Phase 4
10 of 26
2 open now
Registered
24th of 26
by date

Among the 26 studies testing colchicine in Coronary Artery Disease, this one is the 16th largest by planned enrollment, is one of 4 that started in 2026, is one of 10 in phase 4, and was the 24th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

8 of the 26 studies testing colchicine in Coronary Artery Disease are open now, in 3 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About colchicine

Colchicine: first FDA approval 1961 (COLBENEMID), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing colchicine in Coronary Artery Disease, or all of them as a file.
02

Study summary

This study aims to investigate whether TET2-associated clonal hematopoiesis of indeterminate potential (TET2-CHIP) can serve as a biomarker to guide precision use of colchicine in a population of clinically stable post-ACS patients receiving standard of care (SoC) therapy. Specifically, we will evaluate whether TET2-CHIP status predicts a differential response to colchicine. As a pilot study, it also aims to provide detailed data supporting design of further trial, such as sample size calculating, endpoint optimizing, etc.

Read the detailed description

This is a single-center, prospective, randomized, open-label, assessor-blinded pilot trial. A total of 120 patients will be enrolled and stratified by CHIP variant status into a TET2-CHIP group or a non-CHIP group. TET2-CHIP group (N = 60): Participants will be randomized (1:1) to colchicine 0.5 mg once daily plus SoC therapy (n = 30) or SoC therapy alone (control; n = 30). Non-CHIP group (N = 60): Participants will be randomized (1:1) to colchicine 0.5 mg once daily plus SoC therapy (n = 30) or SoC therapy alone (control; n = 30). SoC therapy includes but is not limited to appropriate lipid lowering, anti-platelet therapy, anti-hypertensive and beta blockers as defined by local guidelines. Patients should also be instructed to follow heart healthy (low fat) diet and regular exercise program. The index qualifying ACS must have occurred at least 30 days and no more than 90 days prior to randomization.

Baseline assessment for all participants will include coronary CT angiography (CCTA) using photon-counting detector CT (PCD-CT), inflammatory biomarkers testing and CHIP variant sequencing. After randomization, participants will have visits at Month 0, 1, 3, 6, 9, and 12. Repeat CCTA for the assessment of coronary plaque will occur during the Month 12 visit. The primary endpoint is the percent change in total plaque volume in non-culprit coronary lesion from baseline to Month 12, measured by CCTA. Secondary endpoints include the percent change in other plaques (calcified plaque, noncalcified plaque, low attenuation plaque, and fibrotic plaque) volume of coronary artery plaque from baseline to Month 12; change in levels of inflammatory biomarkers (IL-6, IL-1β, IL-18, hs-CRP, and S100A12); change in the TET2-CHIP variant allele fraction; and major adverse cardiovascular events (MACE), defined as a composite of all-cause death, nonfatal myocardial infarction, nonfatal stroke, and ischemia-driven revascularization. Participants will be followed for 12 months.

03

Conditions studied

  • Colchicine
  • Coronary Atherosclerosis Management
  • Clonal Hematopoiesis of Indeterminate Potential
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 40-85 years;
  2. Patients with recent hospitalization for documented ACS (the index event occurring 30-90 days before randomization) and meeting all of the following:

    1. During the index hospitalization, patients underwent either PCI or diagnostic coronary angiography alone,
    2. At least one non-culprit coronary lesion with 30%-70% diameter stenosis by visual estimation on coronary angiography,
    3. Clinically stable throughout the screening period,
    4. Receiving standard of care therapy for ACS in accordance with national guidelines,
    5. Peripheral blood DNA available for targeted sequencing, with results demonstrating either TET2-CHIP or no CHIP-associated variants;
  3. Written .

Exclusion criteria

Exclusion Criteria:

  1. Prior coronary artery bypass grafting (CABG) before documented ACS;
  2. Other cardiovascular diseases, including moderate-to-severe valvular heart disease (moderate or severe), heart failure ( class III-IV), or atrial fibrillation;
  3. Non-culprit coronary anatomy (e.g., marked tortuosity, bifurcation lesions, or small vessels \<1.5 mm in diameter) deemed to preclude plaque assessment by CCTA;
  4. Planned PCI or CABG;
  5. Abnormal liver function ( >3 times the ) at randomization;
  6. Abnormal renal function (serum creatinine >1.5 times the upper limit of normal range or estimated \<45 mL/min/1.73 m²) at randomization;
  7. Hematologic abnormalities: anemia ( \<100g/L), thrombocytopenia ( count \<100×109/L) or leukopenia (white blood cell \<3×109/L) at randomization;
  8. Inflammatory bowel disease (Crohn's or ulcerative colitis) or active diarrhea;
  9. Symptomatic peripheral neuropathy, pre-existing progressive neuromuscular disease or creatine kinase (CK) level > 3 times the upper limit of normal range as measured within the past 30 days and determined to be non-transient through repeat testing;
  10. Pregnancy, breastfeeding, or women of who are not using an effective method of ;
  11. Any , known allergy or intolerance to colchicine;
  12. Colchicine use within 30 days prior to randomization, or planned colchicine therapy for other indications;
  13. Current or planned use of any of cyclosporine, verapamil, protease inhibitors, azole antifungals, or macrolide antibiotics;
  14. Existing or planned treatment with other anti-inflammatory or drugs;
  15. History of (hematologic or solid-tumor);
  16. History of transplantation (hematopoietic stem cell or solid-organ);
  17. Significant radiation exposure (≥40 mSv) within the past 12 months;
  18. Known to iodinated contrast media or uncontrolled active hyperthyroidism;
  19. Current enrollment in another clinical trial;
  20. A predicted \< 1 year;
  21. Any other circumstances in which the investigator judges that the patient is not suitable to participate in the clinical trial.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Colchicine with SoC therapy (TET2-CHIP group)

    Participants with TET2-CHIP will receive colchicine 0.5 mg orally once daily plus standard of care (SoC) therapy for 12 months.

    Drug: Colchicine 0.5 mg orally once daily for 12 months. · Other: SoC therapy

  • No intervention
    SoC therapy alone (TET2-CHIP group)

    Participants with TET2-CHIP will receive SoC therapy alone (no colchicine) for 12 months.

  • Experimental
    Colchicine with SoC therapy (non-CHIP group)

    Participants without CHIP-associated variants will receive colchicine 0.5 mg orally once daily plus standard of care (SoC) therapy for 12 months.

    Drug: Colchicine 0.5 mg orally once daily for 12 months. · Other: SoC therapy

  • No intervention
    SoC therapy alone (non-CHIP group)

    Participants without CHIP-associated variants will receive SoC therapy alone (no colchicine) for 12 months.

Interventions

  • DrugColchicineStudies of ColchicineColchicine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    SoC therapy includes but is not limited to appropriate lipid lowering, anti-platelet therapy, anti-hypertensive and beta blockers as defined by local guidelines.

  • OtherSoC therapy

    SoC therapy

06

What researchers measure

Primary outcomes

  1. Percent change in total plaque volume of coronary artery plaque

    Percent change in total plaque volume of coronary artery plaque measured by CCTA

    Time frame: Up to 12 months

Secondary outcomes

  1. Percent change in other plaques (calcified plaque, noncalcified plaque, low attenuation plaque, and fibrotic plaque) volume of coronary artery plaque

    Percent change in other plaques (calcified plaque, noncalcified plaque, low attenuation plaque, and fibrotic plaque) volume of coronary artery plaque measured by CCTA.

    Time frame: Up to 12 months

  2. Change in levels of inflammatory biomarkers

    Change in levels of circulating IL-6, IL-1β, IL-18, hs-CRP, and S100A12.

    Time frame: Up to 12 months

  3. Change in TET2-CHIP variant allele fraction at 6 months

    Change in TET2-CHIP variant allele fraction measured by next generation sequencing.

    Time frame: Up to 6 months

  4. Change in TET2-CHIP variant allele fraction at 12 months

    Change in TET2-CHIP variant allele fraction measured by next generation sequencing.

    Time frame: Up to 12months

  5. Major adverse cardiovascular events (MACE)

    A composite of all-cause death, nonfatal myocardial infarction, nonfatal stroke, and ischemia-driven revascularization.

    Time frame: Up to 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2027, 17 months after the start.

Of 181 non-industry phase 4 interventional studies under Coronary Artery Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 17 months is below that.

Counting every sponsor, half of 194 studies reached it within 35 months; a quarter within 20 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2026
First posted
Jan 23, 2026
StartActual
Jun 8, 2026
Primary completionEst.
Dec 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07362966
Lead sponsor
Shenyang Northern Hospital
Responsible party
Han Yaling (MD, PhD, Shenyang Northern Hospital) — Principal investigator
First posted
Jan 23, 2026
Start date
Jun 8, 2026
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Oct 1, 2026

Study contacts

Zaixin Jiang, MD, PhD
Contact
jzxdr2013@163.com
+8618646330195
Yaling Han, MD, PhD
study chair · The General Hospital of Northern Theater Command

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Colchicine

Start the discussion